Study identifier:MB102-059
ClinicalTrials.gov identifier:NCT00908271
EudraCT identifier:N/A
CTIS identifier:N/A
Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
Type 2 Diabetes Mellitus
Phase 1
Yes
Dapagliflozin
Male
7
Interventional
18 Years - 45 Years
Allocation: N/A
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
Bristol-Myers Squibb
The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.
Location
Location
Madison, WI, United States, 53704
Arms | Assigned Interventions |
---|---|
Other: Dapagliflozin PO and IV | Drug: Dapagliflozin Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.